ovplex patent granted in hong kong

HealthLinx Limited
ABN 88 098 640 352
576 Swan Street Richmond VIC 3121
Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
www.healthlinx.com.au
OvPlex™ patent granted in Hong Kong
26 October 2011: HealthLinx Limited (ASX:HTX) has been granted a patent for OvPlex™ in
Hong Kong making it the third jurisdiction to grant such status. HealthLinx’s Intellectual Property
(IP) protection and patent portfolio for OvPlex™ now extends to Australia, the United Kingdom
and Hong Kong. This means that the company has complete freedom to operate in these
jurisdictions.
“The company’s IP portfolio is significantly strengthened by the granting of the OvPlex™ patent
in Hong Kong” said HealthLinx managing director Nick Gatsios. “This is an important milestone
considering the company’s plans to run SFDA approval studies in China to obtain regulatory
approvals to sell OvPlex™ in what will become the worlds largest market, China. This can only
be seen as a prelude to obtaining patent protection in China and further enhancing the
company’s core IP position.”
HealthLinx announced in September that it has entered into a research agreement with
CytogenDx Co Ltd of China to begin a 350 patient academic study as the first step towards
SFDA approvals. The SFDA approval will allow HealthLinx through its partner CytogenDX to
launch OvPlex™ in China and access one of the worlds largest and fastest growing consumer
markets.
In October the company also announced that the OvPlex™ trademark had also been granted in
China, further strengthening the company’s IP position and branding of its core product
OvPlex™.
Please refer to attached certificate for patent details.
Enquiries
Nick Gatsios (HealthLinx Limited) +61 3 9208 4200
About HealthLinx Limited (ASX:HTX)
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial
targets are for diseases with high fatality:
• Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market
• Prostate cancer targeting US$350m pa market
A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.
HealthLinx has commenced the second larger study for OvPlexTM aiming to prove the diagnostic accuracy for early stage
ovarian cancer. This larger study is based on 1150 new samples using existing OvPlex™ biomarkers and including two
novel biomarkers AGR2 and HTX012. The study will be a robust comparison of sensitivity and specificity especially for
early stage diagnosis in symptomatic women. The objective is to cement the position of OvPlex™ as the world’s most
accurate and efficient ovarian cancer diagnostic.
The second study is partially funded with $750,000 from the Victorian Government Victoria’s Science Agenda Investment